Examining Inflammatory Interstitial Lung Disease from a Drug Development Perspective
8:25 am
Chair’s Opening Remarks
Meera Ramanujam
Executive Director, Immunology and Translational Research, Aro Biotherapeutics
8:30 am
Comparing & Contrasting Fibrotic & Inflammatory ILDs in Order to Comprehensively Understand Key Differences in Their Development & Progression & Learning How This Influences Drug Development
1:30 pm
Driving Efficiencies in ILD drug Trials Through Lung Intelligence: How Precision Imaging Biomarkers & an AI-Driven Cloud Platform are Helping Accelerate New Therapies to Patients
2:15 pm
Exploring Endpoints in the Context of Inflammatory ILDs: Debating Which Factors You Must Measure to Accurately Assess the Efficacy of Treatment in Inflammatory vs Fibrotic ILDs
Elizabeth Renzoni
Consultant Respiratory Physician, Honorary Senior Lecturer, Imperial College London